Kythera valuation remains compelling, says Cowen

theflyonthewall.com

Cowen recommends buying Kythera into strength following positive Phase lll US and Canadian results. The firm expects the company's focus to move to its significant commercial opportunity. Shares are Outperform rated with a $50 price target.

View Comments (0)